Tag Archives: Akcea Therapeutics

Analysts’ Perspective: Viacom (VIAB), James River Group (JRVR), Akcea Therapeutics (AKCA)

Investment Analysts at Needham upgraded Viacom Inc. (NASDAQ:VIAB) shares from Hold to Buy rating with a price target of $40.

Viacom, Inc. is a global entertainment content company, which connects with audiences through compelling television programs, motion pictures, short-form video, applications, games, brands for consumer products, social media and other entertainment content.


Brokerage Firm Keefe Bruyette upgraded James River Group Holdings Ltd. (NASDAQ:JRVR) shares from Market Perform to Outperform rating.

James River Group Holdings Ltd. engages in insurance business activities.


Akcea Therapeutics Inc. (NASDAQ:AKCA) shares were upgraded by analysts at Wells Fargo from Market Perform to Outperform rating.

Akcea Therapeutics, Inc. is a late-stage pharmaceutical company, which engages in the development and commercializing of drugs fro the treatment of cardio metabolic diseases caused by lipid disorders.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/